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Abstract
Objective: To characterise the influence of the fat free mass on the metabolite profile in serum samples from participants of
the population-based KORA (Cooperative Health Research in the Region of Augsburg) S4 study.
Subjects and Methods: Analyses were based on metabolite profile from 965 participants of the S4 and 890 weight-stable
subjects of its seven-year follow-up study (KORA F4). 190 different serum metabolites were quantified in a targeted
approach including amino acids, acylcarnitines, phosphatidylcholines (PCs), sphingomyelins and hexose. Associations
between metabolite concentrations and the fat free mass index (FFMI) were analysed using adjusted linear regression
models. To draw conclusions on enzymatic reactions, intra-metabolite class ratios were explored. Pairwise relationships
among metabolites were investigated and illustrated by means of Gaussian graphical models (GGMs).
Results: We found 339 significant associations between FFMI and various metabolites in KORA S4. Among the most
prominent associations (p-values 4.75610
216–8.95610
206) with higher FFMI were increasing concentrations of the
branched chained amino acids (BCAAs), ratios of BCAAs to glucogenic amino acids, and carnitine concentrations. For various
PCs, a decrease in chain length or in saturation of the fatty acid moieties could be observed with increasing FFMI, as well as
an overall shift from acyl-alkyl PCs to diacyl PCs. These findings were reproduced in KORA F4. The established GGMs
supported the regression results and provided a comprehensive picture of the relationships between metabolites. In a sub-
analysis, most of the discovered associations did not exist in obese subjects in contrast to non-obese subjects, possibly
indicating derangements in skeletal muscle metabolism.
Conclusion: A set of serum metabolites strongly associated with FFMI was identified and a network explaining the
relationships among metabolites was established. These results offer a novel and more complete picture of the FFMI effects
on serum metabolites in a data-driven network.
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Introduction
The skeletal muscle mass is a major determinant of energy
requirement of the body. It is a predictor of basal metabolic rate
and energy turn-over during physical activity. In addition, it has
recently been identified as an endocrine organ; producing and
releasing myokines which exhibit various biological effects on the
muscle tissue itself and beyond [1]. Among the most important
effects of muscle mass and activity with respect to chronic diseases
are enhanced fat oxidation, improved insulin sensitivity, and a
reduced body fat mass. The effects of myokines may also be one
explanation for the favourable effects that physical activity exerts
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e40009on human health, e.g. by modulating the immune response. The
skeletal muscle mass accounts for one-third to one-half of total
body protein, depending on gender, age, and health status, and
represents the largest fraction of the fat free body mass [2]. As pure
skeletal muscle mass is difficult to measure in epidemiological
studies, data on fat free mass was used as a proxy instead. Similar
to the body mass index (BMI, kg/m
2), the fat free mass index
(FFMI, kg/m
2) allows for height-independent interpretations and
comparisons between studies [3].
So far, with an enormous effort over 4000 serum and plasma
metabolites belonging to more than 50 different chemical classes
have been identified, validated and characterised in the Serum
Metabolome Database [4]. As this number exceeds the scope of
most studies, a targeted metabolomics approach was chosen for
our studies. The concept of targeted metabolomics is the
quantification of a defined set of metabolites in a body fluid,
representing an image of the current metabolic state of the
organism [5]. It has been shown previously that this method has
the power to identify perturbations of the body’s metabolic
homeostasis and allows for the identification of and access to
biomarkers of metabolic pathways that are impacted for example
by diseases [6–11].
In this study, we took a targeted quantitative metabolomics
approach to identify fat free mass/muscle mass related changes on
human metabolism. To this end, the associations between FFMI
and up to 190 serum metabolite concentrations including amino
acids, acylcarnitines, phosphatidylcholines (PCs), sphingomyelins
as well as hexose and biogenic amines measured by means of two
different kits, were investigated in participants of the population-
based studies KORA S4 and its seven-year follow-up KORA F4.
As the biogenic amines are not part of the KORA F4
metabolomics dataset, the KORA S4 results were not discussed.
However, they are shown in the Table S2. Furthermore, we
computed Gaussian graphical models (GGMs), which have
previously been shown to detect directly related metabolites in
metabolomics data [12]. The resulting partial correlations in
combination with the results from the linear regression models
then provide a comprehensive picture of FFMI effects in a data-
driven metabolic network.
Materials and Methods
Ethics Statement
The study was approved by the ethics committee of the
Bavarian Medical Association. Written informed consent was
obtained from each participant in accordance with institutional
requirements and the Declaration of Helsinki Principles.
Study Design and Population
The present analyses are based on subsamples of the
metabolically characterised participants of the KORA S4 study
and its seven-year follow-up KORA F4 study. KORA (Cooper-
ative Health Research in the Region of Augsburg) is a research
platform performing population-based surveys and subsequent
follow-ups in the region of Augsburg in Southern Germany and
has been described extensively [13]. The metabolic profiles of
1614 subjects in KORA S4 (ageing 54–75 years at the time of
examination) and 3061 subjects in KORA F4 (ageing 31–82 years)
were determined. The bioelectrical impedance analysis measure-
ments of the participants’ body composition (fat free mass and
body fat mass) which are part of the present analyses were only
conducted in KORA S4. In order to account for this, only weight-
stable participants of the KORA F4 population were included in
the present study sample. A person was defined as weight-stable if
their weight gain or loss did not exceed more than 0.5% per year
since their body weight was measured in KORA S4 [14]. Further,
subjects with a known history of myocardial infarction, stroke,
diabetes or cancer were excluded as well as subjects taking ACE
inhibitors or anti-lipidemic drugs. This resulted in a sample size of
n=965 for KORA S4 and n=890 for KORA F4 with an overlap
of n=725 subjects.
Blood Sampling
In both studies, fasting serum samples for metabolic analysis
were collected during study centre visits. For KORA S4, the blood
drawing occurred after a period of overnight-fasting (minimum of
8 hours) using S-MonovetteH serum tubes (SARSTEDT AG &
Co., Nu ¨mbrecht, Germany). Tubes were inverted two to three
times, spent five minutes on the universal shaker (SARSTEDT AG
& Co., Nu ¨mbrecht, Germany) before being allowed to rest for 40
minutes at 4uC for total coagulation. Later on, tubes were
centrifuged for 15 minutes at 2,660 g, serum was separated and
filled into synthetic straws which were stored in liquid nitrogen
(2196uC) until analysis. The collection and procedure for the
KORA F4 samples has previously been described [15].
Metabolite Quantification
Metabolic characterisation of the KORA F4 serum samples was
done in 2009 in three batches of approximately 1000 samples at
three different time points with a recalibration of the equipment in
between; whereas the complete KORA S4 set was characterised in
2011 in one batch.
The targeted metabolomics approach for KORA F4 and S4 was
based on ESI-(LC-) MS/MS measurements by the Absolute-
IDQ
TM p150 kit and p180 kit (BIOCRATES, Life Sciences AG,
Innsbruck, Austria), respectively. The assays allow simultaneous
quantification of 163 (kit p150; F4) or 186 (kit p180; S4)
metabolites out of 10 ml serum in each case. The AbsoluteIDQ
TM
p150 kit has previously been described in detail [15,16]. The p180
kit is an extension of it, using additional LC-MS/MS separation.
For both kits, sample handling was performed by a Hamilton
Micro Lab Star robot (Hamilton Bonaduz AG, Bonaduz,
Switzerland) and a nitrogen evaporator (Porvair, Ultravap). Mass
spectrometry (MS) analyses were done on a 4000 QTRAP mass
spectrometer (AB Sciex) coupled to Promincence HPLC (Shi-
madzu) apparatus (F4) and an API 4000 LC-MS/MS System (AB
Sciex Deutschland GmbH, Darmstadt, Germany) equipped with
an Agilent 1200 Series HPLC and a HTC PAL auto sampler
(CTC Analytics, Zwingen, Switzerland) (S4) controlled by the
software Analyst 1.4 for kit p150 (F4) 1.5.1 for kit p180 (S4). Data
evaluation for quantification of metabolite concentrations and
quality assessment was performed with the MetIQ
TM software
package, which is an integral part of the AbsoluteIDQ
TM kits.
Internal standards serve as reference for the calculation of
metabolite concentrations. The methods of the AbsoluteIDQ
TM
p150 and p180 kits have been proven to be in conformance with
the FDA Guideline [17], which implies proof of reproducibility
within an given error range. Measurements were performed as
described in the manufacturer manuals. Concentrations are
reported in mmol/l.
Metabolite Spectrum
In total, up to 190 different metabolites were quantified. Kit
p150 (KORA F4; 163 metabolites) contains 14 amino acids (13
proteinogenic + ornithine), hexose (sum of hexoses – about 90–
95% glucose), free carnitine and 40 acylcarnitines (Cx:y), 15
sphingomyelins (SMx:y), 77 phosphatidylcholines (PCs, aa=diacyl,
ae=acyl-alkyl) and 15 lyso-phosphatidylcholines (lysoPCs). The
Metabolomics and Fat Free Mass
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the number of carbons in the side chain and y denoting the
number of double-bonds. Kit p180 (KORA S4; 186 metabolites)
includes 21 amino acids (19 proteinogenic + citrulline + ornithine),
hexose, free carnitine, 39 acylcarnitines, 15 sphingomyelins, 90
phosphatidylcholines (14 lysoPC and 76 PCs) as well as 19
biogenic amines. The overlap of both kits is 159 metabolites. Full
biochemical names and abbreviations are provided in Table S1.
Quality Control of the Metabolomics Dataset
The quality control of the metabolomics dataset of KORA F4
was done in a two-step procedure. First, the quality of all
metabolites was assessed using a reference blood which was
measured five times on ten plates. With this data, a coefficient
of variation was calculated for every metabolite and plate. All
metabolites having a mean coefficient of variation over all ten
plates bigger than 25% were removed from the dataset (eleven
in total). One further metabolite was excluded as the number of
missing values exceeded 5%. In the second step, the dataset was
controlled for outliers. A subject’s metabolite concentration was
defined as an outlier if the concentration was greater or less
than the mean 6 five standard deviations of the particular
metabolite over the whole population. All subjects having more
than three independent outlying metabolite concentrations were
excluded from the dataset. An outlier was defined as
independent if the correlation with all other outliers was less
than 70%. If there were three or less independent outliers, only
the data points were removed. All missing values were imputed
with the R package ‘‘mice’’ which uses a linear regression
approach. For the quality control of the KORA S4 metabolite
dataset, a new coefficient of variation was calculated using the
reference blood which was on all KORA S4 plates. The same
quality criteria were applied to the KORA S4 sample, resulting
in 20 metabolites being excluded from the dataset. This left us
with 151 metabolites for the KORA F4 dataset and 166
metabolites for KORA S4, with an overlap of 141 metabolites.
As the metabolic profile in KORA F4 samples was assessed in
three batches a so called batch variable was included in all
analyses of the F4 metabolomics dataset in order to avoid
possible effects due to technical issues or different time points of
analyses. This step was not necessary for the KORA S4 dataset.
Anthropometric and Body Composition Assessment
Height and weight were measured to the nearest 0.1 cm and
0.1 kg, respectively. Waist circumference was measured to the
closest 0.1 cm at the smallest position between the lower rip and
the upper margin of the iliac crest. Hip size was determined
exactly to 0.1 cm as the widest circumference measured between
the upper margin of the iliac crest and the crotch. For the
assessment of body composition, two bioelectrical impedance
analysis measurements of resistance (R), reactance (Xc) and the
phase angle (a) were taken between the dominant hand wrist and
dorsum and the dominant foot angle and dorsum (placement of
the electrodes) by means of a body impedance analyser (BIA 2000-
S; Data Input GmbH, Frankfurt, Germany) while subjects were
spreading their arms and legs and lying in a relaxed and supine
position on a nonconductive surface with 50 kHz. Fat free mass,
fat mass, and the appendicular skeletal muscle mass were then
calculated by means of Kyle’s equations [18,19] on which the
following indices are based: FFMI (fat free mass in kg/(height in
m)
2), body fat mass index (body fat mass in kg/(height in m)
2) and
the appendicular skeletal muscle mass index (appendicular skeletal
muscle mass/(height in m)
2.
Genotyping, Imputation and SNP Selection
In KORA F4, genotyping was done by means of Affymetrix
Human SNP Array 6.0. HapMap CEU version 22 was used as
population reference and as reference for the imputation of the
genotyped SNPs with IMPUTE v0.4.2. The complete procedure
has been described in more detail [15]. The present analysis
includes 170 SNPs. The selection of these SNPs is based on an
extensive literature research of genome-wide association studies
with an anthropometric characteristic as outcome. A list of the
selected SNPs can be found in Table S4.
Statistical Analyses
The descriptive data is presented as mean and standard
deviation for the continuous variables and as absolute quantities
and percentages for the discrete parameters. Sports activity was
defined by the amount of regular leisure time exercise per week;
more than one hour equals active; less equals inactive. The KORA
S4 and F4 samples were analysed as independent cross-sectional
studies. Besides the absolute metabolite concentrations, all pairs of
intra-metabolite class ratios (n=4629 for KORA S4 and n=4518
for KORA F4) were part of the metabolomics datasets.
Associations between metabolite concentrations or metabolite
ratios and the FFMI were assessed by means of linear regression
models. First, metabolite variables (absolute concentrations and
ratios) were standardised with an inverse log-normal transforma-
tion to allow for comparison of the estimates derived from the
linear regression models. Then, linear regression models were
applied with the metabolite variables as dependent variables and
the FFMI as explanatory variable. The models for the KORA S4
metabolomics data were adjusted for sex and age, whereas the
models for KORA F4 were adjusted for age, sex, and batch. To
control for multiple testing and with regard to the dependencies
among the various metabolites and ratios, a p-value of 3.12610
204
for KORA S4 and a p-value of 3.5610
204 for KORA F4 were
considered statistically significant at a=5%. For an association
with a metabolite ratio to be regarded as statistically significant, an
additional criterion (the p-gain) had to be fulfilled next to a
significant p-value. The p-gain is defined as the fold decrease in
the p-value of association for the pair of metabolites compared to
the lowest of the two p-values for the single metabolites [6]. Thus,
an association between a metabolite ratio (M1/M2) and FFMI is
considered to be significant, if the p-value of this association is
significant and the p-gain exceeds a certain value. To calculate the
p-gain we first have to determine the minimum p-value of the
associations between metabolite M1 and FFMI as well as
metabolite M2 and FFMI. The p-gain is the quotient of this
minimum to the p-value of the association between the metabolite
ratio and FFMI. This p-gain had to exceed 170 for KORA S4 and
150 for KORA F4. These cut-offs are seen as Bonferroni-related
corrections in order to identify metabolite concentration pairs for
which the strength of association improves considerably by using
ratios [6].
Stratified analyses. Different sub-analyses were performed.
First, a different main explanatory variable was used. Instead of
FFMI, the appendicular skeletal muscle mass index was included
in the linear regression models with the same adjustments. Second,
stratified analyses were conducted with age, sex, sports activity and
BMI as potential confounders or effect modifiers.
GGMs. In addition to the linear regression analyses, we
investigated the relationships between metabolites as well as the
propagation of FFMI effects through the metabolic network by
means of Gaussian graphical modelling. In order to obtain a GGM,
the partial correlation coefficients between all pairs of metabolites
were calculated [12]. For KORA S4 each partial correlation
Metabolomics and Fat Free Mass
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metabolites and tested for significance. Bonferroni correction was
applied, maintaining a significance level of alpha=0.01. In order to
focus on particularly strong effects between metabolites a cut-off of
r=0.3 (partial correlation coefficient) was applied to the network.
Each node represents a metabolite, whereas edges represent
significant partial correlations. Nodes were coloured according to
the b-estimate and the p-value from the linear models (red =
positive estimate; blue = negative estimate; white = not significant
estimate). The same procedures were applied to the KORA F4
metabolite concentrations including the batch variable as a
confounder.
Genetic analyses. The associations between serum metabo-
lite concentrations or ratios and SNPs which are found to be
associated with anthropometric characteristic were analysed using
linear models with the assumption of additive genetic effects. For
the metabolite concentrations of the genotyped KORA S4 subjects
(n=668), models were adjusted for age and sex. For the analysis
with KORA F4 metabolic data (n=890), adjustments were made
for age, sex and batch. A p-value of 4.73610
206 for S4 and
5.3610
206 for F4 was considered as statistically significant at
a=5%.
AllstatisticalanalyseswereperformedwiththeRsoftwareversion
2.12.0 [R Development Core Team, 2010, http://www.r-project.
org]. The GGMs were visualised by the yEd graph editor version
3.6.1.1 [yWorks Gmbh, http://www.yWorks.com].
Results
Table 1 summarises anthropometric data of the KORA S4 and
F4 participants. Selected statistically significant associations of
FFMI with different metabolite concentrations for the KORA S4
population are given in Table 2. Different parameters such as the
direction of the beta estimate derived from the adjusted linear
model are given, as is the agreement between the KORA S4 and
F4 results. The full list of statistically significant associations
obtained in KORA S4 and F4 can be found in Tables S2 and S3,
respectively. The GGMs established in KORA S4 and F4 are
displayed in Figure 1, 2, and S1, completing the results of the
linear regression models by illustrating the underlying relationships
between the metabolite concentrations.
Amino Acids
With higher FFMI, increasing serum concentrations of the
branched chained amino acids (BCAAs) valine, isoleucine, and
leucine as well as of the sum of BCAAs were observed.
Furthermore, other serum amino acids increased with higher
FFMI, including the glucogenic amino acid alanine, and the
aromatic amino acids tyrosine and phenylalanine. With respect to
metabolite ratios, strong positive associations were found between
FFMI and the ratios of isoleucine/glycine and leucine/glycine. In
addition, the ratio of all BCAAs/all glucogenic amino acids (sum
of alanine, glycine, and serine) was positively related to FFMI,
supporting the notion of increasing BCAAs concentrations in
relationship to glucogenic amino acids in serum samples of
subjects with higher FFMI. Inspecting the GGM results (Figure 1),
we also observe these strong correlations between BCAAs. Based
on these results, we illustrated the association between the sum of
BCAAs and FFMI (by FFMI quintiles) in Figure 3, and described
the anthropometric characteristics of the S4 participants by
BCAAs quintiles (Table 3). We were able to replicate these
findings in the KORA F4 sample (Table S3).
Acylcarnitines
Serum concentrations of free carnitine and short-chain odd-
numbered acylcarnitines, such as propionylcarnitine (C3) and
valerylcarnitine (C5), were found to be positively associated with
FFMI while octadecanoylcarnitine (C18) decreased with increas-
ing FFMI. This is also reflected in the results for the ratios of C18
to C0, C3, or C5. These findings in S4 are supported by the
KORA F4 results. The acylcarnitines form a separate group
within the partial correlation networks and a particularly strong
correlation exists between the metabolites C0 and C3.
Phosphatidylcholines
The group of phosphatidylcholines consists of different PC
diacyl (aa), PC acyl-alkyl (ae), and lysoPC acyl (a) compounds.
Numerous associations between FFMI and PCs or PC ratios could
be observed. An increase in FFMI was associated with (i) a higher
serum concentration of PC aa in relation to PC ae, (ii) a decrease
in chain length of the fatty acid residues, and (iii) a decrease in
saturation (i.e., a higher number of double bonds) of the fatty acid
moieties. Significant results for single PC compounds were all
negatively associated with FFMI, such as PC ae C42:3 or PC ae
C36:2, lysoPC a C18:2 or lysoPC a C18:1; the only exception is
PC aa C38:3 which increased with higher FFMI. Ratios within
subgroups (aa/aa, ae/ae, lyso/lyso) demonstrated that increasing
FFMI is associated with a shift towards shorter fatty acids and fatty
acids with more double bonds. Examples are ratios of PC aa
C38:3/PC aa C42:6, PC aa C38:3/PC aa C42:2, PC aa C38:3/
PC aa C42:0, PC ae C36:4/PC ae C40:1 or lysoPC a C14:0/
lysoPC a C18:2. This is most likely a consequence of the
associations observed for the single compounds (e.g., PC aa C38:3
increased and lysoPC a C18:1 decreased with increasing FFMI).
Ratios of PC aa to PC ae were significantly associated with FFMI,
e.g., PC aa C38:3/PC ae C42:3 or PC aa C38:3/PC ae 42:2.
There are two very large groups of PCs which were identified in
the network analyses (Figure 2). PC aa C38:3 is the centre of one
cluster which includes mainly PC aa and shorter PC ae; the other
cluster consists of mostly long-chain PCs.
These findings are also supported by the results obtained in the
KORA F4 sample.
Sphingomyelins
With higher FFMI an increased concentration of sphingomy-
elins (SM) as compared to hydroxysphingomyelins (SM (OH)) was
observed. This is reflected e.g., by the ratios of SM (OH) C16:1/
SM C18:1, SM (OH) C16:1/SM C18:0 or SM (OH) C22:2/SM
C18:1. Also, the results of SM ratios, such as SM C16:0/SM
C16:1 or SM 16:0/SM C18:1, demonstrate a decrease in
saturation of the fatty acids with increasing FFMI. The same
associations are found in KORA F4. The GGM results show that
almost all SM are interrelated and the strong relationship between
SM (OH) C16:1 and SM (OH) C14:1 is present in both GGMs
(Figure 2 and Figure S1).
Appendicular Skeletal Muscle Mass Index
For both, KORA S4 and F4, the results for the appendicular
skeletal muscle mass index were largely comparable to the results
with FFMI (data not shown). However, the p-values in the linear
regression models did not decrease and also the adjusted R
2 did
not improve as compared to the FFMI-based results. Therefore,
FFMI remained as primary explanatory variable.
Metabolomics and Fat Free Mass
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In stratified analyses, very similar results could be observed for
men and women. With respect to sports activity, there was only a
slight difference between both groups (active versus inactive
participants) for the acylcarnitine metabolites. Most of the
statistically significant associations with FFMI and the acylcarni-
tines were not present in the inactive group. Regarding age (.65
years vs. #65 years; S4), there were no distinct differences between
groups.
With respect to the associations between FFMI and the
metabolites in obese and non-obese subjects in KORA S4 we
did observe significant differences. Most associations described for
the whole population and also noted for the non-obese subgroup
are not present in obese subjects (Table 4).
Genetic Analyses
No significant associations were found between the selected
genetic variants (Table S4) and the serum metabolite concentra-
tions (KORA S4 or KORA F4).
Discussion
In this population-based study, strong associations between
FFMI and serum metabolite concentrations were found in KORA
S4 and reproduced in KORA F4. With higher FFMI, BCAA
serum concentrations and the ratio of BCAAs to glucogenic amino
acids increased. Free carnitine levels were also positively associated
with FFMI, and for the various PCs we found a decrease in chain
length and/or saturation of the fatty acid residues in combination
with higher concentrations of PC aa in expense of PC ae and
lysoPC. In obese subjects of KORA S4, however, these
associations were lacking.
The human serum metabolome is currently characterised in
many studies using different analytic approaches [4], including the
method applied here. To the best of our knowledge, the
association of FFMI/fat free mass and serum metabolites was
not explored before in an epidemiologic setting. Rather,
metabolomics signatures of exercise (before, during and after-
wards) in human plasma were investigated showing that subjects
who were in better shape exhibited more lipolysis during and after
exercise than did the less fit participants [20]. This leads to the
Table 1. Characteristics (mean 6 SD; % or n absolute) of male and female subjects in the analysed samples of KORA S4 and F4.
KORA S4 (n=965) KORA F4 (n=890)
Men Women Men Women
(n=485) (n=480) (n=423) (n=467)
Parameter Unit mean ± SD mean ± SD mean ± SD mean ± SD
Age years 63.2165.53 63.3465.30 53.82612.02 54.66612.48
Weight kg 83.19611.36 71.59612.03 83.19611.37 69.04613.11
Height cm 172.2666.35 159.3365.96 176.6967.03 162.8666.58
Body Mass Index kg/m
2 28.0463.61 28.2364.68 26.6463.25 26.0464.72
Waist cm 100.0169.39 89.60611.05 95.8969.91 85.19612.63
Hip cm 104.7066.49 107.1969.90 104.1766.15 104.1969.37
Waist to Hip Ratio 0.9560.05 0.8360.06 0.9260.06 0.8260.07
Fat Free Mass
a kg 58.4865.74 43.1165.06 60.8266.05 43.5865.39
Body Fat Mass
a %2 9 . 2 5 64.66 39.1964.79 26.3264.95 35.9565.66
FFMI
a, b kg/m
2 19.7161.66 16.9961.85 19.5961.55 16.5061.76
BFMI
a, c kg/m
2 8.3462.29 11.2463.08 7.1762.07 9.6163.15
Parameter Category % (n absolute) % (n absolute) % (n absolute) % (n absolute)
Body Mass Index ,18.5 0 (0) 0 (0) 0.24 (1) 0.64 (3)
18.5–,25 17.11 (83) 25.62 (123) 30.50 (129) 45.82 (214)
25–,30 56.49 (274) 43.33 (208) 52.72 (223) 34.90 (163)
$30 26.19 (127) 30.63 (147) 16.55 (70) 18.63 (87)
Sports Activity
d active 38.76 (188) 46.67 (224) 59.81 (253) 61.24 (286)
inactive 60.41 (293) 52.92 (254) 40.00 (169) 38.76 (181)
Age Groups 31–40 y – – 14.66 (62) 15.42 (72)
41–50 y – – 29.55 (125) 24.2 (113)
51–60 y 38.14 (185) 35.42 (170) 23.88 (101) 26.98 (126)
61–70 y 48.45 (235) 52.08 (250) 21.99 (93) 21.2 (99)
71–80 y 13.4 (65) 12.5 (60) 9.46 (40) 11.56 (54)
$81 y – – 0.47 (2) 0.64 (3)
aParameters derived from the bioelectrical impedance analysis measurements which were only conducted in KORA S4;
bFat Free Mass Index;
cBody Fat Mass Index;
dSports (active: .1 h leisure time of sports per week on a regular basis; inactive: less than 1 h sports per week).
doi:10.1371/journal.pone.0040009.t001
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a in a linear regression model adjusted for age and sex in the
KORA S4 sample.
Trait Mean SD Dir.
b adj. P-value
c R
2 adj.
d P-gain
e F4
f
(mmol/l)
Val 227.26 53.13 pos. 4.75610
216 0.16 *
Glu 80.13 32.04 pos. 1.22610
215 0.11 n.a.
Ile 72.14 20.22 pos. 1.96610
211 0.22 #
Leu 160.51 44.33 pos. 2.57610
208 0.18 #
Ala 417.99 101.4 pos. 8.95610
206 0.03 n.a.
Tyr 72.09 20.06 pos. 4.77610
210 0.06 *
Phe 76.73 17.19 pos. 2.53610
207 0.05 n.s.
S aromatic AAs 208.98 43.75 pos. 3.37610
209 0.07 *
SBCAAs 459.91 113.06 pos. 2.07610
213 0.19 *
Ile/Gly 0.29 0.11 pos. 1.61610
214 0.30 1.22610
+03 #
Leu/Gly 0.65 0.25 pos. 1.46610
212 0.29 1.75610
+04 #
S BCAAs/S glucogenic AAs 0.58 0.14 pos. 1.49610
208 0.26 *
C5 0.16 0.06 pos. 3.49610
205 0.17 *
C3 0.47 0.15 pos. 4.85610
205 0.13 *
C0 40.52 8.49 pos. 1.19610
202 0.13 *
C18 0.06 0.01 neg. 3.96610
202 0.10 n.s.
C18/C5 0.37 0.14 neg. 1.44610
209 0.08 2.42610
+04 n.s.
C18/C3 0.13 0.05 neg. 3.65610
209 0.05 1.33610
+04 n.s.
C18/C0 0.001 0.0004 neg. 5.44610
207 0.05 2.19610
+04 n.s.
PC aa C38:3 57.77 14.01 pos. 7.02610
206 0.06 *
PC ae C42:3 0.85 0.19 neg. 5.10610
218 0.10 *
PC ae C36:2 15.33 3.88 neg. 2.42610
215 0.19 *
lysoPC a C18:2 28.46 9.04 neg. 8.19610
216 0.16 *
lysoPC a C18:1 21.61 6.1 neg. 2.30610
210 0.11 *
S PC ae 181.45 30.52 neg. 1.38610
204 0.10 *
S lysoPC 229.29 47.21 neg. 4.36610
204 0.07 *
PC aa C38:3/PC aa C42:6 97.71 21.87 pos. 1.04610
217 0.09 6.73610
+11 *
PC aa C38:3/PC aa C42:1 228.35 80.97 pos. 6.09610
215 0.07 1.15610
+07 *
PC aa C38:3/PC aa C42:0 111.66 41.58 pos. 1.06610
215 0.07 3.68610
+06 *
PC aa C38:3/PC aa C42:2 297.65 96.51 pos. 1.72610
216 0.10 1.69610
+09 *
lysoPC a C14:0/lysoPC a C18:2 0.24 0.08 pos. 1.04610
220 0.18 7.88610
+04 n.s.
PC ae C36:4/PC ae C40:1 12.99 3.34 pos. 1.70610
207 0.04 3.57610
+02 *
PC aa C38:3/lysoPC a C18:1 2.27 0.99 pos. 3.37610
220 0.19 2.43610
+04 *
PC aa C38:3/lysoPC a C18:2 2.87 1.03 pos. 1.38610
219 0.17 1.66610
+09 *
PC aa C38:3/PC ae C42:3 70.43 21.88 pos. 3.12610
226 0.12 1.63610
+08 *
PC aa C38:3/PC ae C36:2 3.98 1.36 pos. 8.17610
225 0.13 2.96610
+09 *
PC aa C38:3/PC ae C42:2 93.08 24.28 pos. 3.73610
223 0.11 7.97610
+15 *
SM C16:0/SM C16:1 6.4 0.76 neg. 1.52610
211 0.29 3.13610
+08 *
SM (OH) C16:1/SM C18:1 0.31 0.06 neg. 3.51610
210 0.05 4.94610
+07 *
SM C16:0/SM C18:1 9.36 1.83 neg. 5.71610
208 0.24 8.33610
+04 *
SM (OH) C16:1/SM C18:0 0.16 0.03 neg. 3.28610
210 0.10 5.27610
+07 *
SM (OH) C22:2/SM C18:1 1.00 0.19 neg. 4.14610
207 0.05 2.93610
+05 *
aFat Free Mass Index;
bdirection of the association (positive or negative);
cfor multiple testing adjusted p-value;
dadjusted R
2 of the linear model;
ep-gain, fold decrease in the p-value of association for the pair of metabolites, compared to the lowest of two p-values for the single metabolites;
fconfirmed in KORA F4, for * significance and direction; # confirmed for xLeu in F4, n.a., metabolite was not available in F4; AAs, amino acids; S aromatic amino acids,
sum of tyrosine, phenylalanine, and tryptophan; S BCAAs, sum of valine, isoleucine, and leucine; S glucogenic amino acids, sum of alanine, glycine, and serine.
The full results are given in Tables S2 (KORA S4) and S3 (KORA F4).
doi:10.1371/journal.pone.0040009.t002
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e40009Figure 1. Gaussian graphical model of serum amino acids and acylcarnitine metabolite concentrations in KORA S4. Each node
represents a metabolite, whereas edges represent significant partial correlations. Nodes were coloured according to the b-estimate and the p-value
from the linear models (red = positive association with FFMI; blue = negative association with FFMI; white = not significant association with FFMI).
doi:10.1371/journal.pone.0040009.g001
Figure 2. Gaussian graphical model of serum glycerophospholipids and sphingolipid metabolite concentrations in KORA S4. Each
node represents a metabolite, whereas edges represent significant partial correlations. Nodes were coloured according to the b-estimate and the p-
value from the linear models (red = positive association with FFMI; blue = negative association with FFMI; white = not significant association with
FFMI). Yellow highlights both large clusters within the glycerophospholipid metabolites.
doi:10.1371/journal.pone.0040009.g002
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PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e40009Figure 3. Boxplot of serum BCAA concentrations (mmol/l), by quintiles of the FFMI, for the KORA S4 population.
doi:10.1371/journal.pone.0040009.g003
Table 3. Different characteristics of the KORA S4 population stratified by quintiles of the serum BCAA
a concentration, given as
mean and SD as well as percentage and absolute quantity.
Quintiles of the sum of BCAAs
Quintile 1 2 3 4 5
(mmol/l) (163.5–363.7) (364.1–418) (418.2–476.9) (477–542.2) (542.3–963)
Age 63.0865.41 63.2765.38 63.565.62 63.665.42 62.9465.29
Weight 69.45611.77 75.562.72 76.11611.18 81.64612.39 84.32611.93
Height 161.3567.48 164.6568.73 165.7769.13 168.8668.77 168.5168.38
Body Mass Index 26.6464.08 27.8564.27 27.7564 28.6363.75 29.7964.15
Fat Free Mass (kg) 44.1367.34 49.4169.08 50.1968.72 54.7568.83 55.7268.12
Body Fat Mass (%) 36.166.34 34.3766.88 3467.15 32.7366.82 33.7466.68
FFMI
b 16.8762.02 18.1162.25 18.1562.05 19.0961.89 19.5561.89
BFMI
c 9.7762.88 9.7463.08 9.663.15 9.5462.97 10.2563.24
FFM/BFM
d 1.8960.81 2.0560.73 2.0860.69 2.1960.67 2.0960.66
Male 19.69% (38) 42.49% (82) 49.74% (96) 67.88% (131) 71.5% (138)
Female 80.31% (155) 57.51% (111) 50.26% (97) 32.12% (62) 28.5% (55)
Sports activity
e 47.15% (91) 35.75% (69) 52.33% (101) 40.93% (79) 37.31% (72)
aBCAAs, sum of valine, isoleucine, and leucine;
bFat Free Mass Index;
cBody Fat Mass Index;
dFat Free Mass divided by Body Fat Mass;
eSports (active: .1 h leisure time of sports per week on a regular basis; inactive: less than 1 h sports per week).
doi:10.1371/journal.pone.0040009.t003
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skeletal muscle metabolism that favour the development of obesity
and metabolic diseases. In fact, our observation that associations
found between FFMI and serum metabolites were largely missing
in obese subjects at baseline (S4) fits well to the hypothesis of a
deranged skeletal muscle metabolism. As observed by Lewis et al.
[20], a decreased capability to stimulate lipid oxidation during
exercise could be reflected in the missing associations between
FFMI and the various lipid metabolites in obese subjects. For the
non-obese participants, we find evidence for an enhanced ß-
oxidation with higher FFMI which is reflected in the carnitine and
PC metabolite results.
In contrast to a study with physical activity intervention, it was
not clear how strong associations between FFMI and serum
concentrations of amino acids, acylcarnitines, glycerophospholi-
pids, and sphingolipids could be in a cross-sectional study with
collection of serum samples after short-term fasting of at least eight
hours. However, our results fit well to biological pathways that are
related to skeletal muscle metabolism, namely amino acid
Table 4. Selected metabolic traits significantly associated with FFMI
a in a linear regression model adjusted for age, and sex for the
non-obese and obese participants in the KORA S4 sample.
Obese (BMI $30 kg/m
2)
(n=274)
Non-obese (BMI,30 kg/m
2)
(n=691)
beta adj. P-value
b R
2 adj.
c beta adj. P -value
b R
2 adj.
c
Val 0.08 1.00 0.03 0.14 1.70610
204 0.17
Ile 0.06 1.00 0.12 0.13 3.94610
204 0.25
Leu 0.04 1.00 0.08 0.13 3.77610
204 0.22
Ala 0.02 1.00 0.00 0.12 0.0409 0.02
Tyr 0.04 1.00 0.00 0.14 2.09610
203 0.05
Phe 0.06 1.00 0.00 0.10 0.2377 0.04
S aromatic AAs 0.05 1.00 0.02 0.12 0.014 0.06
S BCAAs 0.06 1.00 0.07 0.15 5.10610
205 0.21
Ile/Gly 0.03 1.00 0.26 0.13 2.42610
204 0.30
Leu/Gly 0.02 1.00 0.22 0.13 9.29610
205 0.30
S BCAAs/glucogenic AAs 0.05 1.00 0.15 0.10 0.0353 0.30
C5 0.06 1.00 0.13 0.14 1.34610
204 0.19
C3 0.06 1.00 0.06 0.13 2.52610
203 0.16
C0 0.06 1.00 0.08 0.09 0.255 0.16
PC aa C38.3 0.00 1.00 0.02 0.08 1.00 0.04
PC ae C42.3 20.14 0.31 0.04 20.16 7.30610
205 0.06
PC ae C36.2 20.07 1.00 0.13 20.09 0.418 0.17
lysoPC a C18.1 20.08 1.00 0.08 20.07 1.00 0.05
lysoPC a C18.2 20.14 0.21 0.13 20.07 1.00 0.08
S PC ae 20.04 1.00 0.05 20.05 1.00 0.09
S lysoPC 20.04 1.00 0.06 20.02 1.00 0.04
PC aa C38:3/PC aa C42:6 0.03 1.00 0.01 0.18 2.69610
206 0.05
PC aa C38:3/PC aa C42:2 0.05 1.00 0.03 0.14 7.49610
204 0.05
lysoPC a C14:0/lysoPC a C18:2 0.18 0.003 0.17 0.10 0.113 0.09
PC aa C38:3/lysoPC a C18:1 0.07 1.00 0.11 0.11 0.0377 0.10
PC aa C38:3/lysoPC a C18:2 0.10 1.00 0.13 0.10 0.158 0.11
PC aa C38:3/PC ae C42:3 0.10 1.00 0.01 0.18 8.77610
207 0.05
PC aa C38:3/PC ae C36:2 0.06 1.00 0.04 0.14 1.48610
203 0.06
PC aa C38:3/PC ae C42:2 0.07 1.00 0.00 0.17 1.02610
205 0.04
SM C16:0/SM C16:1 20.02 1.00 0.23 20.06 1.00 0.27
SM (OH) C16:1/SM C 18:1 0.01 1.00 0.01 20.08 1.00 0.02
SM C 16:0/SM C 18:1 20.02 1.00 0.17 20.06 1.00 0.23
SM (OH) C16:1/SM C 18:0 0.02 1.00 0.17 20.10 0.170 0.05
SM (OH) C22:2/SM C 18:1 0.00 1.00 0.05 20.07 1.00 0.01
aFat Free Mass Index;
bfor multiple testing adjusted p-value;
cadjusted R
2 of the linear model; AAs, amino acids; S aromatic amino acids, sum of tyrosine, phenylalanine, and tryptophan; S BCAAs, sum of valine, isoleucine, and
leucine; S glucogenic amino acids, sum of alanine, glycine, and serine.
doi:10.1371/journal.pone.0040009.t004
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and glycerophospholipids).
BCAAs are described as a preferred substrates for muscle tissue,
and BCAA supplementation can suppress protein degradation
[21]. During short-term fasting, glucose released from glycogen
stores of the liver is provided as fuel for tissues that need glucose
(e.g. brain). Muscle protein degradation provides amino acids that
are used by the liver for gluconeogenesis [22], with alanine being
the most important one. BCAAs are a major source of nitrogen for
muscle synthesis of glucogenic amino acids such as alanine
[23,24]. This has been shown in studies with 1–3 days of
starvation. Levels of BCAAs rise in fasting state parallel to an
increased protein degradation. In this state, the only source of
BCAAs is appearance from protein degradation, which is a key
process for maintenance of protein quality and repair process of
tissues. Thus, during overnight fasting, BCAA serum concentra-
tions are increased proportional to the muscle mass of the body.
Furthermore, alanine concentration levels rise with increasing
protein degradation during starving [21]. Thus, our findings of
increasing serum concentrations of BCAAs and alanine that are
strongly associated with FFMI are in line with the expectations.
Several other studies reported that acylcarnitines are also found
in circulation [4]. Acylcarnitines are intra-cellularly synthesized for
the transport of fatty acids into the mitochondria for b-oxidation.
In the present analyses an increase of acylcarnitine concentrations
could be observed which argues for an upregulated b-oxidation of
fatty acids in subjects with higher muscle mass. One explanation
for the origin of propionylcarnitine is oxidative degradation (b-
oxidation, c-oxidation) of BCAAs, releasing propionylcarnitine
units. Another source of propionyl residues may be the intestinal
production by gut microbiota; however a relationship with plasma
propionylcarnitine or FFMI is not established.
Our phospholipid results point towards a decrease in chain
length and degree of saturation of the lipid side chains. The
concentrations of lysoPC and PC ae decrease with increasing
FFMI and PC aa C38:3 is the only PC positively associated with
higher FFMI. Considering the GGM results, PC aa C38:3 is
central in one cluster of PC metabolites, while the other cluster
consists of long chain PCs. Overall, our results implicate that
FFMI is associated with lower plasma concentrations of very long
chain PCs (GGM cluster 2), while the concentration of PC aa
C38:3 increased. Thus, a higher FFMI might indicate a higher
activity of enzymes involved in fatty acid oxidation, especially in
the oxidation of very-long chain fatty acids. In addition, an altered
activity of enzymes involved in chain elongation (ELOVL) or
desaturation (FADS) could contribute to these findings. Earlier
studies using metabolomics and genetic data could demonstrated
that genetic effects (mediated by the expression of enzymes) are
reflected in the serum metabolic profile, thus lending credibility to
the approach of identifying enzyme activities by means of serum
metabolites or ratios of serum metabolites [15,25]. The shift from
PC ae and lysoPC towards PC aa could also be explained by
modifications in expression or activity of relevant enzymes [15].
However, analyses of the association between selected SNPs which
are known to be associated with anthropometric characteristics did
not reveal any significant relationship with metabolite ratios.
In addition, a higher FFMI was found to be associated with an
increased concentration of sphingomyelins as compared to
hydroxysphingomyelins. Recently, Wang-Sattler et al. [26]
reported a reduced concentration of SM and an increased
concentration of SM (OH) in smokers. This finding was explained
as a consequence of smoking on the activity of the peroxisomal
enzyme alkylglycerone phosphate synthase (alkyl-DHAP). Follow-
ing the same line of argumentation, FFMI is probably associated
with an increase of the activity of alkyl-DHAP. The negative
association of the SM C16:0/SM C16:1 ratio with FFMI might be
explained by regulatory processes in the fatty acid biosynthesis
pathway. In particular, stearoyl-CoA desaturase (SCD), which
catalyses the desaturation of C16 and C18 fatty acids, might be a
target enzyme/gene affected by greater muscle mass and/or
activity.
Strength and Limitations
The participants of our studies represent random samples of the
underlying population. In such a population with a heterogeneous
metabolic makeup influenced by different environmental factors,
genetic predispositions, and lifestyles, the interpretation of
metabolic profiling is quite ambitious [6]. The metabolite
concentrations which are reported in the present paper were
identified by means of two slightly different AblsoluteIDQ
TM kits
p150 and p180. These two kits are not identical (190 different
metabolites were measured with an overlap of 141) and the
measurement method of the amino acids slightly differs. However,
this technology allows the automated quantification of hundreds of
metabolites for many samples at a time which is very helpful for
future studies [27]. Furthermore, the side chain composition of the
different PCs, lysoPCs, sphingomyelins and acylcarnitines carries
many information on the different fatty acid pools in the human
body, such as n23 and n26 polyunsaturated fatty acids or
saturated and mono-saturated short and medium chain fatty acids
[28]. Thus, the kit is well oriented to map out the human lipidome
and therefore particular for the purpose of this study.
The bioelectrical impedance analysis measurements did only
take place in KORA S4. For the analyses of associations between
FFMI and the metabolite concentrations in KORA F4 only the
results of the bioelectrical impedance analysis measurements at
baseline examination (KORA S4) were available. Assuming that
the participants’ body composition is fairly stable in weight-stable
subjects, the KORA F4 based analyses were restricted to the
weight-stable subjects in order to account for this.
For the current analysis, subjects with a diagnosis of diabetes or
hypertension or medication for both diseases were excluded.
However, obese subjects are more likely to develop derangements
in glucose or lipid metabolism as compared to normal-weight
subjects which are in a subclinical state and have not led to a
clinical diagnosis yet. An analysis of serum glucose (hexose) and
triacylglycerol indicated significantly different means between non-
obese and obese subjects. In non-obese subjects, mean 6 SD
serum glucose concentration was 5.1860.76 mmol/l and mean
serum triacylglycerol concentration was 1.460.81 mmol/l; the
corresponding values in obese subjects were 5.661.11 mmol/l
and 1.7061.05 mmol/l, respectively. However, the higher glucose
and triacylglycerol concentrations in obese do not indicate a
catabolic status and thus are not sufficient to explain the missing
association between FFMI and serum metabolites.
Stratified analyses by gender, age, and sports activity were
conducted in order to detect potential confounders and effect
modifiers. Similar results were found for men and women
separately. P-values increased, as the sample size within the strata
(slightly more for men) was smaller, but there was no improvement
of the model fit, represented by the adjusted R
2. In addition, the
FFMI is independent of height [3] thus taking one difference
between men and women into account. Furthermore, analysing
the whole sample increases the power and we were able to cover a
wider range of the FFMI. With respect to sports activity, slight
differences were found for the acylcarnitine metabolite group.
There, these effects were no longer present within the inactive
subjects. However, as sports activity and FFMI are correlated and
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mass, sports activity was not included as a covariate in the main
analyses.
The GGMs present low levels of linkage between the
metabolites which is in line with findings from Krumsiek et al.
[12] who demonstrated that GGMs omit indirect correlations.
Nevertheless, the GGMs complete the linear regression results
with the underlying relationships between the metabolites.
Conclusion
We found strong associations between serum amino acids,
acylcarnitines, and glycerophospholipids with the FFMI in a
population-based sample. These findings were stable as they could
be reproduced in a follow-up study of this population. Most
interestingly, such associations were largely missing in obese
subjects. The latter finding supports the hypothesis that a
sedentary lifestyle associated with accumulation of fat tissue may
be accompanied by a derangement in skeletal muscle metabolism,
especially a limited inducibility of fatty acid oxidation.
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